ANDA 65346, held by Fresenius Kabi USA. Clindamycin Phosphate.
As of Nov 15, 2026, ANDA 65346 (Clindamycin Phosphate), held by Fresenius Kabi USA, was first approved by FDA on Mar 29, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin PhosphateEQ 150MG BASE/ML ยท injectable;injection | Clindamycin Phosphate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
